Previous close | 238.26 |
Open | 236.28 |
Bid | 234.19 x 200 |
Ask | 234.83 x 200 |
Day's range | 233.31 - 237.71 |
52-week range | 204.44 - 261.54 |
Volume | |
Avg. volume | 474,509 |
Market cap | 11.027B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 11.83 |
EPS (TTM) | 19.80 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 295.18 |
United Therapeutics (UTHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 26, 2024--Please replace the photo for release dated April 24, 2024 with the accompanying corrected photo.
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.